1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Neurogenetic Testing Market, By Type
5.1 Introduction
5.2 Microarray Analysis
5.3 Whole-Exome Sequencing (WES)
5.4 Multiplex Ligation Dependent Probe Amplification (MLPA)
5.5 Polymerase Chain Reaction (PCR) Tests
5.6 Other Types
6 Global Neurogenetic Testing Market, By End User
6.1 Introduction
6.2 Hospitals
6.3 Specialty Clinics
6.4 Research Institutes
6.5 Diagnostics Laboratories
6.6 Other End Users
7 Global Neurogenetic Testing Market, By Geography
7.1 Introduction
7.2 North America
7.2.1 US
7.2.2 Canada
7.2.3 Mexico
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.3.3 Italy
7.3.4 France
7.3.5 Spain
7.3.6 Rest of Europe
7.4 Asia Pacific
7.4.1 Japan
7.4.2 China
7.4.3 India
7.4.4 Australia
7.4.5 New Zealand
7.4.6 South Korea
7.4.7 Rest of Asia Pacific
7.5 South America
7.5.1 Argentina
7.5.2 Brazil
7.5.3 Chile
7.5.4 Rest of South America
7.6 Middle East & Africa
7.6.1 Saudi Arabia
7.6.2 UAE
7.6.3 Qatar
7.6.4 South Africa
7.6.5 Rest of Middle East & Africa
8 Key Developments
8.1 Agreements, Partnerships, Collaborations and Joint Ventures
8.2 Acquisitions & Mergers
8.3 New Product Launch
8.4 Expansions
8.5 Other Key Strategies
9 Company Profiling
9.1 Invitae Corporation
9.2 Ambry Genetics
9.3 PerkinElmer
9.4 GeneDx
9.5 Centogene
9.6 Blueprint Genetics
9.7 Genomic Health (Exact Sciences)
9.8 Fulgent Genetics
9.9 QIAGEN
9.10 Baylor Genetics
List of Tables
Table 1 Global Neurogenetic Testing Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
Table 3 Global Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
Table 4 Global Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
Table 5 Global Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
Table 6 Global Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
Table 7 Global Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
Table 8 Global Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
Table 9 Global Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
Table 10 Global Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 11 Global Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
Table 12 Global Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
Table 13 Global Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
Table 14 North America Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
Table 15 North America Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
Table 16 North America Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
Table 17 North America Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
Table 18 North America Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
Table 19 North America Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
Table 20 North America Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
Table 21 North America Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
Table 22 North America Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
Table 23 North America Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 24 North America Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
Table 25 North America Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
Table 26 North America Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
Table 27 Europe Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
Table 28 Europe Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
Table 29 Europe Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
Table 30 Europe Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
Table 31 Europe Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
Table 32 Europe Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
Table 33 Europe Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
Table 34 Europe Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
Table 35 Europe Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
Table 36 Europe Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 37 Europe Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
Table 38 Europe Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
Table 39 Europe Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
Table 40 Asia Pacific Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
Table 41 Asia Pacific Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
Table 42 Asia Pacific Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
Table 43 Asia Pacific Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
Table 44 Asia Pacific Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
Table 45 Asia Pacific Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
Table 46 Asia Pacific Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
Table 47 Asia Pacific Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
Table 48 Asia Pacific Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
Table 49 Asia Pacific Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 50 Asia Pacific Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
Table 51 Asia Pacific Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
Table 52 Asia Pacific Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
Table 53 South America Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
Table 54 South America Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
Table 55 South America Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
Table 56 South America Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
Table 57 South America Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
Table 58 South America Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
Table 59 South America Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
Table 60 South America Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
Table 61 South America Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
Table 62 South America Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 63 South America Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
Table 64 South America Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
Table 65 South America Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
Table 66 Middle East & Africa Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
Table 67 Middle East & Africa Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
Table 68 Middle East & Africa Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
Table 69 Middle East & Africa Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
Table 70 Middle East & Africa Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
Table 71 Middle East & Africa Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
Table 72 Middle East & Africa Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
Table 73 Middle East & Africa Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
Table 74 Middle East & Africa Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
Table 75 Middle East & Africa Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 76 Middle East & Africa Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
Table 77 Middle East & Africa Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
Table 78 Middle East & Africa Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
| ※参考情報 神経遺伝学的検査とは、神経系の疾患や障害に関連する遺伝的な要因を調べるための検査です。この検査を通じて、遺伝子の変異や異常を特定し、それによって神経疾患のリスクや原因を明らかにすることができます。神経遺伝学的検査は、特に神経系に特有の疾患に関連する遺伝情報を提供し、診断や治療方針の決定に役立つ重要な手段です。 神経遺伝学的検査の種類には、大きく分けていくつかのタイプがあります。まずは「単一遺伝子検査」です。この検査は、特定の遺伝子に焦点を当て、その遺伝子に変異があるかどうかを確認します。例としては、ハンチントン病や筋ジストロフィーなどの遺伝疾患があります。次に「多遺伝子パネル検査」があり、これは複数の遺伝子を一度に解析する方法です。このアプローチは、特定の症状や疾患群に関連する多くの遺伝子を同時に評価することができ、診断精度を高めるのに役立ちます。 「全エクソーム検査」や「全ゲノム検査」もあります。全エクソーム検査は、遺伝子の中でタンパク質をコードしている部分、すなわちエクソンを対象にした検査です。一方、全ゲノム検査は、ゲノム全体を解析し、より広範な情報を提供します。これにより、既知の疾患だけでなく、未知の疾患リスクについても情報を得ることができるため、より包括的な理解が可能になります。 神経遺伝学的検査の用途は多岐にわたります。まず、診断において、特定の神経疾患を確認したり、その原因を特定したりするために使用されます。特に、症状が似ている神経疾患が多いため、遺伝的な情報は正確な診断に寄与します。また、家族性疾患のリスク評価や、遺伝カウンセリングの一環としての利用もあります。子どもを持つことを希望するカップルが遺伝的リスクを理解するための助けとなることもあります。 さらに、治療方針の決定にも役立つことから、神経遺伝学的検査は個別化医療の重要な要素となっています。具体的には、特定の遺伝子変異に基づいて治療薬の効果が異なる場合があるため、病気に最も適した治療法を選ぶための手掛かりとなります。 関連技術としては、次世代シーケンシング（NGS）が挙げられます。これは、遺伝子の配列を高速かつ正確に解析する技術であり、神経遺伝学的検査の効率と精度を大幅に向上させています。この技術により、大量の遺伝データを迅速に取得できるため、研究や臨床応用においても革新的な進展が見られています。 また、バイオインフォマティクスも重要な役割を果たしています。遺伝子データの解析や解釈を行うための計算技術であり、複雑なデータを整理し、疾患との関連性を導き出すための支援をします。これにより、より正確な診断や効果的な治療法の選択が可能となるのです。 神経遺伝学的検査は、神経系の疾患に対する理解を深め、診断・治療に革新をもたらす重要な手段です。今後もこの分野は進化し、より多くの人々の健康に寄与することが期待されています。知識や技術が進展することで、神経疾患の早期発見や治療の向上が図られ、多くの患者にとって希望となることでしょう。神経遺伝学的検査は、医学の未来においてますます重要な役割を果たすことが予想されます。 |
